• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Catheter Precision Inc.

    11/14/24 5:12:56 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care
    Get the next $VTAK alert in real time by email
    SC 13G/A 1 armistice-vtak093024a1.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*



    Catheter Precision, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.0001 per shar

    (Title of Class of Securities)

     

    74933X609

    (CUSIP Number)

     

     

    September 30, 2024
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    o Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  74933X609
     SCHEDULE 13G/A
    Page 2 of 8 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Armistice Capital, LLC
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    105,743
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    105,743
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    105,743
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    9.99%
    12
    TYPE OF REPORTING PERSON
     
    IA, OO

     


     

    CUSIP No.  74933X609
     SCHEDULE 13G/A
    Page 3 of 8 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Steven Boyd
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States of America
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    105,743
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    105,743
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    105,743
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    9.99%
    12
    TYPE OF REPORTING PERSON
     
    IN, HC

     


     

     

    CUSIP No. 74933X609
     SCHEDULE 13G/A
    Page 4 of 8 Pages

     

    Item 1.(a) Name of Issuer

    Catheter Precision, Inc.

    Item 1.(b) Address of Issuer’s Principal Executive Offices

    1670 Highway 160 West, Suite 205

    Fort Mill, South Carolina 29708

    Item 2.(a) Names of Person Filing:

    Armistice Capital, LLC

    Steven Boyd

    Collectively, the "Reporting Persons"

      

    Item 2.(b) Address of Principal Business Office:

     

    Armistice Capital, LLC

    510 Madison Avenue, 7th Floor

    New York, New York 10022

    United States of America

     

    Steven Boyd

    c/o Armistice Capital, LLC

    510 Madison Avenue, 7th Floor

    New York, New York 10022

    United States of America

      

    Item 2.(c) Citizenship:

     

    Armistice Capital, LLC - Delaware

    Steven Boyd - United States of America

      

    Item 2.(d) Title of Class of Securities

     

    Common Stock, par value $0.0001 per share (“Shares”)

     

    Item 2.(e) CUSIP No.:

    74933X609

     

    CUSIP No.  74933X609
     SCHEDULE 13G/A
    Page 5 of 8 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) x A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
           

     

    CUSIP No. 74933X609
     SCHEDULE 13G/A
    Page 6 of 8 Pages

     

     

    Item 4. Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a) Amount beneficially owned as of September 30, 2024:

    Armistice Capital, LLC - 105,743

    Steven Boyd - 105,743   

    (b) Percent of Class as of September 30, 2024:

    Armistice Capital, LLC - 9.99%

    Steven Boyd - 9.99% 

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote

    Armistice Capital, LLC - 0

    Steven Boyd - 0 

    (ii) Shared power to vote or to direct the vote

    Armistice Capital, LLC - 105,743

    Steven Boyd - 105,743  

    (iii) Sole power to dispose or to direct the disposition of

    Armistice Capital, LLC - 0

    Steven Boyd - 0 

    (iv) Shared power to dispose or to direct the disposition of

    Armistice Capital, LLC - 105,743

    Steven Boyd - 105,743

    The percentage of Shares reported to be beneficially owned by the Reporting Persons are based on information from the Issuer.

    Armistice Capital, LLC (“Armistice Capital”) is the investment manager of Armistice Capital Master Fund Ltd. (the "Master Fund"), the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund. Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund. The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

     

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

    The Master Fund, a Cayman Islands exempted company that is an investment advisory client of Armistice Capital, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

    Not Applicable.

    Item 8. Identification and Classification of Members of the Group

    Not Applicable.

    Item 9. Notice of Dissolution of Group 

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
    CUSIP No. 74933X609
     SCHEDULE 13G/A
    Page 7 of 8 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 14, 2024

     

     

     

     

    Armistice Capital, LLC

           
      By:  /s/ Steven Boyd
       

    Steven Boyd

    Managing Member

           

           
      By:  /s/ Steven Boyd
       

    Steven Boyd

           

     

     
    CUSIP No. 74933X609
     SCHEDULE 13G/A
    Page 8 of 8 Pages

     

    Exhibit I

     

    JOINT FILING STATEMENT

     

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G/A, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G/A, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Dated: November 14, 2024

     

     

    Armistice Capital, LLC

           
      By:  /s/ Steven Boyd
       

    Steven Boyd

    Managing Member

           
     

     
      By:  /s/ Steven Boyd
       

    Steven Boyd

           
    Get the next $VTAK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VTAK

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VTAK
    SEC Filings

    View All

    Catheter Precision Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Catheter Precision, Inc. (0001716621) (Filer)

    6/8/26 6:16:04 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Catheter Precision Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Catheter Precision, Inc. (0001716621) (Filer)

    5/18/26 4:17:11 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Catheter Precision Inc.

    10-Q - Catheter Precision, Inc. (0001716621) (Filer)

    5/18/26 7:22:56 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    $VTAK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $VTAK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Flyte (VTAK) Makes Strategic Investment in Volato (SOAR)

    ATLANTA, June 08, 2026 (GLOBE NEWSWIRE) -- Flyte, the regional air mobility subsidiary of Catheter Precision, Inc. (NYSE:VTAK), focused on making private aviation more accessible and flexible for modern travelers, today announced that it has made a strategic investment in Volato Group, Inc. (NYSE:SOAR). As part of the transaction, VTAK acquired approximately 2.9 million shares of SOAR and will own approximately 7.5% of the company's outstanding common stock. This investment provides a basis to explore potential future collaboration to improve access, efficiency, and innovation across private aviation. "This strategic investment represents an exciting opportunity for both organizations,"

    6/8/26 10:43:33 AM ET
    $SOAR
    $VTAK
    Transportation Services
    Consumer Discretionary
    Medical/Dental Instruments
    Health Care

    Volato Group Announces $2.2 Million Strategic Investment and AI Infrastructure Acquisition Focus

    Investment strengthens balance sheet as Company evaluates non-binding AI infrastructure and technology transaction opportunities Volato Group, Inc. (NYSE:SOAR) (the "Company" or "Volato"), a technology company focused on building scalable software and data solutions that improve the reliability and intelligence of high-stakes business decisions, today announced the signing of a definitive agreement to obtain a $2.2 million strategic investment lead by Catheter Precision, Inc. (NYSE:VTAK), and other institutional investors with experience investing in artificial intelligence and emerging technology companies. The investment of restricted common stock will strengthen Volato's balance shee

    6/8/26 6:15:00 AM ET
    $SOAR
    $VTAK
    Transportation Services
    Consumer Discretionary
    Medical/Dental Instruments
    Health Care

    FLYTE ACTIVATES HIGH-FREQUENCY PREAKNESS FLIGHT PROGRAM, DEPLOYING FLEET TO SERVE STRONG NORTHEAST DEMAND

    Company Deploys Scalable Short-Haul Model Following Kentucky Derby to Monetize Peak Travel Window Flagship Routes from NYC, Boston, DC, and Philadelphia Positioned to Drive Immediate Revenue, High Utilization, and Dense Flight Activity NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Flyte, the regional air mobility subsidiary of Catheter Precision, Inc. (NYSE:VTAK) ("VTAK" or the "Company"), today announced the positioning of aircraft across the Northeast to support increased travel demand this coming weekend in anticipation of the Preakness Stakes on Saturday, May 16th. The program centers on Baltimore/Washington International Airport (BWI), the primary access point for race attendees, wit

    5/12/26 8:00:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Jenkins David A

    4 - Catheter Precision, Inc. (0001716621) (Issuer)

    3/30/26 5:58:17 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Anderson Philip J

    4 - Catheter Precision, Inc. (0001716621) (Issuer)

    3/30/26 5:58:15 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Arno Andrew

    4 - Catheter Precision, Inc. (0001716621) (Issuer)

    3/30/26 5:58:11 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    $VTAK
    Leadership Updates

    Live Leadership Updates

    View All

    Catheter Precision, Inc. Announces New Chief Financial Officer

    FORT MILL, SC / ACCESSWIRE / January 7, 2025 / Catheter Precision, Inc. (NYSE:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced that it has brought on board Philip Anderson, to take on the position of Chief Financial Officer. Margrit Thomassen, who has been our Interim Chief Financial Officer, will continue with the company in the role of Controller.David Jenkins, CEO of Catheter Precision, commented on the hire, "After some time of searching for the right fit, we are happy to have concluded our search with Phil Anderson joining the team. His background includes executive management across a variety of industries, managing hedge fund

    1/7/25 8:00:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Catheter Precision, Inc. (NYSE American:VTAK) Presenting at the Sequire Investor Summit in Puerto Rico

    FORT MILL, SC / ACCESSWIRE / January 22, 2024 / Catheter Precision, Inc. (NYSE:VTAK), (the Company) a pioneering U.S. based medical device company committed to enhancing the well-being of patients with cardiac arrhythmias, is pleased to declare its participation in the forthcoming Sequire Investor Summit 2024. The eagerly awaited event, slated for January 23-25, 2024, at the Condado Vanderbilt Hotel in San Juan, Puerto Rico, is poised to provide a spectrum of compelling opportunities for funds, companies, and investors.Puerto Rico has become a hub for family offices, funds, and affluent investors, thanks to its advantageous tax benefits. It stands out as one of the rare locations globally wh

    1/22/24 8:00:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    $VTAK
    Financials

    Live finance-specific insights

    View All

    Catheter Precision Reports 2025 Results and Updates on Strategic Expansion

    Clinical, Commercial and Regulatory Milestones Achieved in 2025 Establish a Strong Foundation in Life Sciences as Revenue Increases 95% Year Over Year Acquisition of Flyte and Strengthened Capital Position Unlock Multi-Segment Growth Strategy with Multiple Near-Term Catalysts FORT MILL, S.C., March 31, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK) ("VTAK" or the "Company"), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the fourth quarter and full year ended December 31, 2025 as well as certain other business updates. 2025: Execution Across Clin

    3/31/26 8:00:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    CRTD (Creatd Inc.) Sells Remaining 80% of Fly Flyte to NYSE-Listed VTAK (Catheter Precision Inc.), Securing Significant Cash and Equity Position

    NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Creatd, Inc. (OTCQB:CRTDD) today announced that it has sold its remaining 80% equity stake in its subsidiary, Fly Flyte, Inc. ("Flyte"), to Catheter Precision, Inc. (NYSE:VTAK). Under the terms of the completed transaction, Creatd will receive approximately $6,000,000 in cash and nearly $6,000,000 in Convertible Preferred Stock of VTAK. The NYSE-approved transaction considerably strengthens Creatd's balance sheet. The sale is consistent with Creatd's strategy of developing turnkey operating solutions that prepare businesses for listing on the public markets while simultaneously retaining a minority interest in them. The transaction positions Cr

    3/10/26 8:00:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    VTAK Acquires 20% Interest in Creatd's Subsidiary Fly Flyte, Inc.

    Strategic Partnership: Creatd expanded Fly Flyte's investor network by adding NYSE-listed VTAK as an investor in its subsidiary.Portfolio Expansion: Creatd continues advancing its portfolio strategy through multiple active acquisition discussions.Innovation in Aviation: Fly Flyte, Inc. is transforming regional aviation through accessibility, convenience, and technology-driven operations. NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Creatd, Inc. (OTCQB:CRTD) announced that Catheter Precision, Inc. (NYSE:VTAK) has acquired a 20% equity interest in Fly Flyte, Inc., its subsidiary, through a secondary purchase from an existing shareholder. The transaction aligns with Creatd's strategy of nurtu

    2/17/26 2:17:42 PM ET
    $CRTD
    $VTAK
    Publishing
    Consumer Discretionary
    Medical/Dental Instruments
    Health Care

    $VTAK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Catheter Precision Inc.

    SC 13G/A - Catheter Precision, Inc. (0001716621) (Subject)

    11/14/24 5:12:56 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Catheter Precision Inc.

    SC 13G/A - Catheter Precision, Inc. (0001716621) (Subject)

    11/13/24 11:14:58 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by Catheter Precision Inc.

    SC 13D/A - Catheter Precision, Inc. (0001716621) (Subject)

    10/30/24 5:26:20 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care